99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This exploratory study conducted under the RDRC program studies the biodistribution of
99mTc-PSMA-I&S in patients with prostate cancer who undergo pelvic lymph node dissection.
Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative
intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I&S) labeled
with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I&S may detect
PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to
detect prostate cancer that has spread to the lymph nodes.